Roles of tumour localization, second signals and cross priming in cytotoxic T-cell induction
暂无分享,去创建一个
Rolf M. Zinkernagel | Hans Hengartner | Adrian F. Ochsenbein | R. Zinkernagel | S. Hemmi | H. Hengartner | S. Sierro | B. Odermatt | A. Ochsenbein | U. Karrer | M. Pericin | J. Hermans | Bernhard Odermatt | Sophie Sierro | Marcus Pericin | Urs Karrer | Jan Hermans | Silvio Hemmi
[1] T. Dimpfl,et al. Cytokeratin-positive cells in the bone marrow and survival of patients with stage I, II, or III breast cancer. , 2000, The New England journal of medicine.
[2] R. Zinkernagel,et al. Escape of thymocytes and mature T cells from clonal deletion due to limiting tolerogen expression levels. , 1994, Cellular immunology.
[3] E. Jaffee,et al. Role of bone marrow-derived cells in presenting MHC class I-restricted tumor antigens. , 1994, Science.
[4] L. Old. Tumor immunology: the first century. , 1992, Current opinion in immunology.
[5] Y. Wu,et al. T cell costimulation by B7/BB1 induces CD8 T cell-dependent tumor rejection: an important role of B7/BB1 in the induction, recruitment, and effector function of antitumor T cells , 1994, The Journal of experimental medicine.
[6] M. Bevan. Cross-priming for a secondary cytotoxic response to minor H antigens with H-2 congenic cells which do not cross-react in the cytotoxic assay , 1976, The Journal of experimental medicine.
[7] Lieping Chen,et al. Can Co‐stimulated Tumor Immunity be Therapeutically Efficacious? , 1995, Immunological reviews.
[8] M. Battegay,et al. Fibroblasts as efficient antigen-presenting cells in lymphoid organs. , 1995, Science.
[9] P. Matzinger. Tolerance, danger, and the extended family. , 1994, Annual review of immunology.
[10] D. Pardoll,et al. Induction of antigen-specific T cell anergy: An early event in the course of tumor progression. , 1998, Proceedings of the National Academy of Sciences of the United States of America.
[11] P. Bruggen,et al. Tumor antigens recognized by T lymphocytes. , 1994, Annual review of immunology.
[12] C. Melief,et al. Specific T Helper Cell Requirement for Optimal Induction of Cytotoxic T Lymphocytes against Major Histocompatibility Complex Class II Negative Tumors , 1998, The Journal of experimental medicine.
[13] P. Linsley,et al. Costimulation of antitumor immunity by the B7 counterreceptor for the T lymphocyte molecules CD28 and CTLA-4 , 1992, Cell.
[14] H. Pircher,et al. Tumor-infiltrating lymphocytes exhibiting high ex vivo cytolytic activity fail to prevent murine melanoma tumor growth in vivo. , 1998, Journal of immunology.
[15] R. Zinkernagel,et al. Virus‐specific major MHC class II‐restricted TCR‐transgenic mice: effects on humoral and cellular immune responses after viral infection , 1998, European journal of immunology.
[16] R. Schwartz. Costimulation of T lymphocytes: the role of CD28, CTLA-4, and B7/BB1 in interleukin-2 production and immunotherapy , 1992, Cell.
[17] D. Harlan,et al. Mice expressing both B7-1 and viral glycoprotein on pancreatic beta cells along with glycoprotein-specific transgenic T cells develop diabetes due to a breakdown of T-lymphocyte unresponsiveness. , 1994, Proceedings of the National Academy of Sciences of the United States of America.
[18] P. Romero,et al. OmpA targets dendritic cells, induces their maturation and delivers antigen into the MHC class I presentation pathway , 2000, Nature Immunology.
[19] P. Klenerman,et al. Immune surveillance against a solid tumor fails because of immunological ignorance. , 1999, Proceedings of the National Academy of Sciences of the United States of America.
[20] I. Hermans,et al. Antigen expressed on tumor cells fails to elicit an immune response, even in the presence of increased numbers of tumor-specific cytotoxic T lymphocyte precursors. , 1998, Cancer research.
[21] J. Allison,et al. Tumor rejection after direct costimulation of CD8+ T cells by B7-transfected melanoma cells. , 1993, Science.
[22] J. Yewdell,et al. Mechanisms of exogenous antigen presentation by MHC class I molecules in vitro and in vivo: implications for generating CD8+ T cell responses to infectious agents, tumors, transplants, and vaccines. , 1999, Advances in immunology.
[23] E. Jaffee,et al. A reassessment of the role of B7-1 expression in tumor rejection , 1995, The Journal of experimental medicine.
[24] S. Kaufmann,et al. The role of cell-mediated immunity in bacterial infections. , 1981, Reviews of infectious diseases.
[25] S. Korsmeyer,et al. On the Key Role of Secondary Lymphoid Organs in Antiviral Immune Responses Studied in Alymphoplastic (aly/aly) and Spleenless (Hox11− /−) Mutant Mice , 1997, The Journal of experimental medicine.
[26] J. Miller,et al. Cross-presentation: a general mechanism for CTL immunity and tolerance. , 1998, Immunology today.
[27] K P Lee,et al. Differential T cell costimulatory requirements in CD28-deficient mice. , 1993, Science.
[28] M. Marić,et al. Maturation of cytotoxic T lymphocytes against a B7-transfected nonmetastatic tumor: a critical role for costimulation by B7 on both tumor and host antigen-presenting cells. , 1998, Cancer research.
[29] R. Offringa,et al. Protective antitumor immunity induced by immunization with completely allogeneic tumor cells. , 1996, Cancer research.
[30] D. Pardoll,et al. Cd40-Independent Pathways of T Cell Help for Priming of Cd8+ Cytotoxic T Lymphocytes , 2000, The Journal of experimental medicine.